mTOR inhibitor + tacrolimus

mTOR inhibitor + tacrolimus is a combination immunosuppressive regimen consisting of a mammalian target of rapamycin (mTOR) inhibitor and the calcineurin inhibitor tacrolimus. mTOR inhibitors, such as sirolimus and everolimus, inhibit the mTORC1 complex, which is a key regulator of cell growth and proliferation, particularly in T-cells. Tacrolimus binds to FKBP12 to form a complex that inhibits calcineurin, thereby blocking the dephosphorylation of NFAT and the subsequent production of interleukin-2 (IL-2). This dual-mechanism approach is used in solid-organ transplantation to prevent graft rejection. In clinical research, such as the HORUS-COPE trial led by Oriol Manuel, this combination is being explored for its potential to modulate immune responses and control cytomegalovirus (CMV) replication in transplant recipients, as mTOR inhibitors have been associated with lower rates of CMV infection compared to other immunosuppressive agents like mycophenolic acid (MPA).

Other names

mammalian target of rapamycin inhibitor + tacrolimusmTORi + tacrolimusmTOR inhibitor + tacrolimus